Acorda adds to PD portfolio with Biotie takeout

Acorda Therapeutics Inc. (NASDAQ:ACOR) will acquire Biotie Therapies Corp. (HSE:BTH1V; NASDAQ:BITI) for about $363 million in cash. The deal gives Acorda two clinical stage programs for Parkinson's disease, including oral selective adenosine A2A receptor ( ADORA2A) antagonist tozadenant

Read the full 384 word article

How to gain access

Continue reading with a
two-week free trial.